![Survival curves for inhibitor development ([A] any inhibitor; [B] high-titer inhibitor) according to the presence or absence of NNAs. See Figure 1 in the article by Cannavò et al that begins on page 1245.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/129/10/10.1182_blood-2017-01-760538/4/blood760538f1.jpeg?Expires=1735558502&Signature=jYNXBEmGwciHfFOq9OB4~RDBHh4JMo6LpmGu6UTqSvBamzqsRZggurHRVZSA9d9JIxoIoo69hd6bs5y~yqqTL8LrCW4XF~sW9jjpZ9l1iUBgvGQqwhtFNBUcQhYclSteTJVAgd1D2cTHabkUXh-EYuBZsInQODlYJr1gCM7KnGW7K7YEu8zCiTmi-CwLjodhU-BchnPlh-PtK9gkfjLUZ3ZxVAOAOdZGacLtgY5GcCGo-2gHziqnrUyXUI46nvksv~vWQd87R964c17UL50oc15WvUqNoN9UKsH6e0HObiAy7e35FaK65e4nfQJ6TBRw-w3D2gZXVrTHFL3asp3hXQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Survival curves for inhibitor development ([A] any inhibitor; [B] high-titer inhibitor) according to the presence or absence of NNAs. See Figure 1 in the article by Cannavò et al that begins on page 1245.
Survival curves for inhibitor development ([A] any inhibitor; [B] high-titer inhibitor) according to the presence or absence of NNAs. See Figure 1 in the article by Cannavò et al that begins on page 1245.
